Altimmune beats Q2 2026 EPS estimates, shares advance
Biopharmaceutical company reports earnings per share above consensus as investors react positively to financial performance.
Altimmune reported second-quarter 2026 earnings per share that exceeded Wall Street estimates, driving a rise in its shares on Tuesday.
The Gaithersburg, Maryland-based biopharmaceutical firm said adjusted earnings per share for the quarter ended June 30 stood at 12 cents, surpassing the 8-cent consensus estimate compiled by Refinitiv. Revenue for the period totaled $15.3 million, slightly below the $16.1 million forecast.
Shares of Altimmune climbed 4.2% in premarket trading following the release of the results, reflecting investor approval of the earnings beat. The company did not provide updated guidance during the earnings call, though management highlighted progress in its pipeline, including clinical trial updates for its lead candidate.
Analysts at William Blair maintained their outperform rating on the stock, citing the earnings beat and potential for pipeline catalysts. The firm’s price target remains at $12, implying limited near-term upside from current levels.
Altimmune’s performance underscores ongoing investor focus on biopharmaceutical firms amid evolving healthcare market dynamics.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
